Axsome Therapeutics, Inc. (FRA:19X)

Germany flag Germany · Delayed Price · Currency is EUR
128.40
0.00 (0.00%)
At close: Dec 5, 2025
37.65%
Market Cap 6.40B
Revenue (ttm) 478.36M
Net Income (ttm) -195.63M
Shares Out n/a
EPS (ttm) -3.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20
Average Volume 41
Open 125.60
Previous Close 128.40
Day's Range 125.60 - 128.40
52-Week Range 70.00 - 135.55
Beta n/a
RSI 57.99
Earnings Date Feb 13, 2026

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 683
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 19X
Full Company Profile

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.